Alzheimer's disease
Conditions
Interventions
Exposed group:18F-SynVesT-1 PET / CT imaging
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
45 Years to 95 Years
Inclusion criteria
Inclusion criteria: Patients who visited the Department of Neurology of Peking University Shenzhen Hospital between October 2023 and September 2028 were included in this cohort . The inclusion criteria are: 1 The subject voluntarily or legal guardian agrees to participate in this trial and signed the informed consent. 2. Age 45 and 95 years old (subject to the date of signed informed consent), gender is not limited. 3. CU, MCI, and AD patients meeting the NIA-AA diagnostic criteria. 4 Expected survival time of more than 12 months. 5. Willing and able to comply with diagnostic plans, clinical laboratory tests, and other trial procedures.
Exclusion criteria
Exclusion criteria: Subjects will be excluded from this study if any of the following conditions exist: (1) the presence of neoplastic or significant cerebrovascular lesions; (2) neurosurgical or other neurological diseases, including epilepsy, encephalitis, or stroke; (3) clinically related mental illness; (4) current or recent history of drug or alcohol abuse / dependence. 2.There are thyroid dysfunction, vitamin B12 and folic acid deficiency, anemia, and neurosyphilis that may affect cognitive function. 3.Metabolic, immune, severe cardiac, liver, lung, renal disease, or tumors of any type were excluded. 4.Previous radionuclide administration and less than 10 physical half-lives apart from this study. 5.Is going or planning to participate in any drug or device clinical trial during the study. 6.Known allergy to the injection solution or its excipients. 7.Do not lie flat or remain still during the PET scan, or do not tolerate the PET scan. 8.Subjects with abnormalities in physical examination, ECG, EEG and clinical laboratory tests during the screening period that may affect safety or compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical dementia rating;Standardized Uptake Value ratio; | — |
Secondary
| Measure | Time frame |
|---|---|
| asymmetry index; | — |
Countries
China
Contacts
Public ContactMengjie Dong
PekingUniversityShenzhenHospital
Outcome results
None listed